DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 12:56:25 2024-05-28 pm EDT | ||
| 405.3 EUR | -1.20% |
|
| Current month | +9.45% | ||
| 1 month | +9.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 405.3 | -1.20% |
| 24-05-27 | 410.2 | +0.22% |
| 24-05-24 | 409.4 | +0.10% |
| 24-05-23 | 409 | +0.47% |
| 24-05-22 | 407 | +0.74% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 12:56 pm EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7WVA |
| ISIN | DE000ME7WVA4 |
| Date issued | 2024-01-30 |
| Maturity | 2024-06-21 (24 Days) |
| Parity | 1 : 1 |
| Emission price | 383.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 410.2 € |
|---|---|
| Lowest since issue | 363.9 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.57%
- Stock Market
- Certificates
- Certificat
